Skip to main content
SBFM
NASDAQ Life Sciences

Sunshine Biopharma Finalizes $6.0M Public Offering with 240% Immediate Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.447
Mkt Cap
$2.237M
52W Low
$0.281
52W High
$2.43
52W Position info
59% above low
Off High info
82% below high
Rel. Volume info
4.5× avg
Market data snapshot near publication time

SBFM sits 59% above its 52-week low of $0.281 on elevated volume (4.5× avg).

Summary

Sunshine Biopharma finalized a $6.0 million public offering, securing $5.0 million in net proceeds but causing immediate dilution of approximately 240% to existing shareholders.


Key Events · Financing and Capital Events · SBFM

  • Public Offering Finalized

    Sunshine Biopharma finalized a $6.0 million public offering of 11,160,000 common units and 840,000 pre-funded units. Each common unit consists of one share of common stock and two Series C Warrants, while each pre-funded unit includes one pre-funded warrant and two Series C Warrants.

  • Significant Dilution

    The offering will immediately issue 12,000,000 new shares (from common units and pre-funded warrants), representing approximately 240% dilution to the 5,005,945 shares outstanding prior to the offering. An additional 24,000,000 shares could be issued upon exercise of the Series C Warrants.

  • Capital Infusion

    The company expects to receive approximately $5.0 million in net proceeds after deducting placement agent fees and estimated offering expenses. These funds are designated for general corporate purposes, including working capital.

  • Offering Price Details

    Units were priced at $0.50 per common unit (or $0.49999 per pre-funded unit). The Series C Warrants have an initial exercise price of $0.50 per share and are exercisable for five years.


Analysis · SBFM · Life Sciences

Sunshine Biopharma has finalized a $6.0 million public offering of common units and pre-funded units, each including shares and Series C Warrants. This offering will immediately issue 12 million new shares, representing approximately 240% dilution to existing shareholders. The company will receive an estimated $5.0 million in net proceeds, which is critical for its operations given its recent worsening Q1 financials, increased cash burn, and ongoing Nasdaq delisting concerns. While the capital infusion provides a lifeline, the extreme dilution significantly impacts the ownership stake of current shareholders.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 51.3% of the 191 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SBFM was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.28 to $2.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SBFM - Latest Insights

SBFM
Oct 22, 2026, 9:25 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $0.1638
Real-time Price: $2.75 info
Change: Reverse Stock Split info
Market Cap: $2.089M info
SBFM
Oct 14, 2026, 5:21 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.232
Real-time Price: $2.75 info
Change: Reverse Stock Split info
Market Cap: $2.089M info
SBFM
Oct 09, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3269
Real-time Price: $2.75 info
Change: Reverse Stock Split info
Market Cap: $2.089M info
SBFM
Oct 09, 2026, 5:24 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $0.3205
Real-time Price: $2.75 info
Change: Reverse Stock Split info
Market Cap: $2.089M info
SBFM
Oct 09, 2026, 11:17 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.373
Real-time Price: $2.75 info
Change: Reverse Stock Split info
Market Cap: $2.089M info